Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAAPNASDAQ:AEHAWNASDAQ:NEXINASDAQ:NTHI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAAPAdvanced Accelerator Applications$81.63$0.00$35.11▼$82.74N/AN/AN/AN/AAEHAWAesther Healthcare Acquisition$0.01$0.02$0.06▼$0.33N/AN/A34,287 shsN/ANEXINexImmune$0.05$0.00▼$7.05N/A1.987,749 shs14 shsNTHINeonc Technologies$7.22-1.5%$7.76$4.11▼$25.00N/AN/A82,858 shs19,966 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAAPAdvanced Accelerator Applications0.00%0.00%0.00%0.00%0.00%AEHAWAesther Healthcare Acquisition0.00%-31.85%-47.47%-59.23%-89.37%NEXINexImmune0.00%0.00%0.00%-99.90%-100.00%NTHINeonc Technologies-1.50%-3.60%+24.48%+721,999,900.00%+721,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAAPAdvanced Accelerator ApplicationsN/AN/AN/AN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAAPAdvanced Accelerator Applications 0.00N/AN/AN/AAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAAPAdvanced Accelerator ApplicationsN/AN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ANTHINeonc Technologies$79.99KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAAPAdvanced Accelerator ApplicationsN/AN/A0.00∞N/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ANEXINexImmune-$32.34M-$18.54N/AN/AN/AN/A-534.32%-213.72%N/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest AAAP, AEHAW, NTHI, and NEXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NTHINeonc TechnologiesN/A-$2.10N/A-$2.10N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAAPAdvanced Accelerator ApplicationsN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAAPAdvanced Accelerator ApplicationsN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/ANEXINexImmuneN/A0.660.66NTHINeonc TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAAPAdvanced Accelerator ApplicationsN/AAEHAWAesther Healthcare AcquisitionN/ANEXINexImmune9.85%NTHINeonc TechnologiesN/AInsider OwnershipCompanyInsider OwnershipAAAPAdvanced Accelerator ApplicationsN/AAEHAWAesther Healthcare AcquisitionN/ANEXINexImmune14.90%NTHINeonc TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAAPAdvanced Accelerator ApplicationsN/AN/AN/ANot OptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableNEXINexImmune61.40 million1.19 millionNot OptionableNTHINeonc Technologies8N/AN/AN/AAAAP, AEHAW, NTHI, and NEXI HeadlinesRecent News About These CompaniesNeonc technologies CFO Garnett Keithly acquires $976 in sharesMay 23 at 8:37 PM | investing.comInsider Buying: Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Buys 1,400 Shares of StockMay 20, 2025 | insidertrades.comWhy NeOnc Technologies Holdings, Inc.’s (NTHI) Stock Is Up 5.30%May 10, 2025 | aaii.comWhy NeOnc Technologies Holdings, Inc.’s (NTHI) Stock Is Down 5.06%April 23, 2025 | aaii.comNeOnc Technologies announces global patent portfolio totals 176April 16, 2025 | markets.businessinsider.comNeOnc Sees Share Price Fall Since Going PublicApril 15, 2025 | labusinessjournal.comNeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of ...April 15, 2025 | bakersfield.comNeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical MarketsApril 15, 2025 | markets.businessinsider.comNeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01April 15, 2025 | markets.businessinsider.comNeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical MarketsApril 15, 2025 | globenewswire.comNeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in SeptemberApril 14, 2025 | markets.businessinsider.comNeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in SeptemberApril 14, 2025 | globenewswire.comNeOnc Technologies appoints Heshmatpour as PresidentApril 10, 2025 | markets.businessinsider.comFrom Lab to Life: How NeOnc Technologies Accelerates Innovative Therapies to PatientsApril 10, 2025 | gsabusiness.comNeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New PresidentApril 10, 2025 | finance.yahoo.comNeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New PresidentApril 10, 2025 | globenewswire.comNeOnc Technologies announces NEO212 trial nears full enrollmentApril 8, 2025 | markets.businessinsider.comNeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer TherapyApril 8, 2025 | markets.businessinsider.comNeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer TherapyApril 8, 2025 | globenewswire.comNeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer TherapyApril 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAAP, AEHAW, NTHI, and NEXI Company DescriptionsAdvanced Accelerator Applications NASDAQ:AAAPAdvanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.Aesther Healthcare Acquisition NASDAQ:AEHAW$0.01 0.00 (0.00%) As of 05/22/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.NexImmune NASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Neonc Technologies NASDAQ:NTHI$7.22 -0.11 (-1.50%) As of 05/23/2025 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
